Nadareishvili Z, Malashkhia Y, Bakhutashvili V; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 344 (abstract no. PO-B08-1254).
Institute of Medical Biotechnology, Tbilisi, Republic of Georgia.
Plaferon is human placental amnionic interferon, possessing antiviral and immunomodulating properties. Plaferon is natural mixture of peptides which are purified and ready to use for injection. 12 intravenous drug users (IVDU) at age 18-45 with Herpes zoster ganglioneuritis (HZG) were treated with Plaferon. Patients were injected twice in day 10(4) units of Plaferon for 15 days. The control group consisted 10 IVDU with HZG at the same age, who were treated with Prednisolone (70 mg per os daily). All patients were HIV negative. Patients who were treated with Plaferon have had normal number of CD3, CD4 and CD8 cells in comparison with control group, which is followed by positive dynamics of neurologic symptoms. None of patients treated with Plaferon have had postherpetic neuralgia and 4 IVDU with HZG from 10 have had postherpetic pain. Plaferon was invented in the Institute of Medical Biotechnology of Georgian Academy of Sciences and can be recommended for the treatment of viral infections.
Publication Types:
Keywords:
- Antiviral Agents
- Drug Therapy, Combination
- Herpes Zoster
- Herpesvirus 3, Human
- Humans
- Interferon Alfa-2a
- Interferon Alfa-2b
- Interferons
- Neuralgia
- Neuropeptides
- drug therapy
- plaferon
- therapy
Other ID:
UI: 102204163
From Meeting Abstracts